Portola Pharmaceuticals

Portola Pharmaceuticals is a Biotechnology company. It is having more than 380 employees and has offices around the globe and serves patients in more than 50 countries. The company has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS) as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder. The headquarters is in USA.

Alexion acquired Portola Pharmaceuticals for 1.41 billion USD.